Company Description: IMMEDIATE Therapeutics is a late-stage biotech company developing IMT-358, a first-in-class cardioprotective metabolic therapy for use in acute coronary syndromes (ACS), high-risk surgeries, trauma, and other ischemic emergencies and backed by $40M in NIH funding. IMT-358 is a proprietary, protocolized GIK (glucose-insulin-potassium) formulation that addresses a critical gap in care - preserving cardiac tissue before reperfusion or predictable surgical stress. In an 871-patient Phase 2 trial, IMT-358 demonstrated a 50% reduction in cardiac arrest or mortality and a 80% reduction in infarct size. With FDA Breakthrough Therapy, SPA, and BLA designations, a single pivotal Phase 3 trial is planned for 2026. IMT-358 has broad applicability across cardiovascular, surgical, and oncology settings, and is designed for seamless integration into real-world workflows.

Goal for Presentation: Showcase breakthrough cardioprotective therapeutic with high top-line revenue potential to secure strategic investment and partnering interest for IMT-358’s pivotal Phase 3 development and global commercialization.

Additional Comments:

Who referred you to this application?: